SEBI Upholds Ban on Par Drugs' ₹95 Crore Sale to Promoter

Introduction: SEBI Reinforces Shareholder Protection

The Securities and Exchange Board of India (SEBI) has upheld its earlier decision to block the proposed sale of Par Drugs and Chemicals Ltd.'s core business to an entity linked to its promoters. In a confirmatory order issued on March 25, 2026, the market regulator reiterated its concerns over potential irregularities in the transaction's valuation, shareholder communication, and voting process. This decision reinforces the interim order from September 2025, effectively keeping the ₹95 crore deal on hold pending a thorough investigation. The move underscores SEBI's commitment to safeguarding the interests of public shareholders against transactions that may not be fair or transparent.

The Proposed Transaction Under Scrutiny

The issue originated in December 2024, when Par Drugs and Chemicals, a Vadodara-based manufacturer of active pharmaceutical ingredients (APIs), announced its plan for a slump sale of its primary business undertaking. On February 14, 2025, the company signed a Business Transfer Agreement (BTA) with Phal-Jig Fine Chemicals Pvt Ltd (PJFCPL) for a lump sum consideration of ₹95 crore. According to SEBI's findings, PJFCPL is part of the promoter group of Par Drugs, making it a related-party transaction. The company had stated its intention to use the proceeds to venture into a new business, with the sale expected to be completed by September 20, 2025.

SEBI's Initial Intervention and Key Concerns

Following a complaint from shareholders alleging the deal was structured to benefit promoters at their expense, SEBI launched a preliminary investigation. The complaint claimed that the company's core profit-making business was being transferred at an artificially low valuation. Based on its initial findings, SEBI issued an ex-parte interim order on September 15, 2025, restraining Par Drugs from proceeding with the sale. The regulator cited a prima facie view that the deal could be detrimental to public shareholders. SEBI's Whole-Time Member, Kamlesh Chandra Varshney, noted that allowing the transaction to proceed could cause "grave injustice" and would be "irreversible upon execution."

Severe Erosion in Market Value

The announcement and subsequent developments surrounding the slump sale had a significant negative impact on the company's market value. Data revealed a stark decline in Par Drugs' market capitalization, which plummeted by nearly 70%. Before the sale was announced in December 2024, the company's market capitalization stood at ₹428.76 crore. By September 2025, it had eroded to just ₹139.74 crore. This sharp fall correlated directly with key events, including the board's decision, the outcomes of extraordinary general meetings (EGMs), and the final shareholder approval, indicating a loss of investor confidence.

Regulatory Directives for a Fair Assessment

To ensure a fair and independent assessment, SEBI has issued specific directives. The regulator has instructed the National Stock Exchange (NSE) to appoint an independent registered valuer to re-examine the business undertaking. This new valuation must adhere to recognized standards and methodologies to ascertain the true value of the assets being transferred. Following the submission of the valuation report, the NSE must also obtain a fairness opinion from a merchant banker. Par Drugs, its management, and all signatories to the BTA have been ordered to cease and desist from any actions that could lead to the disposal of assets until further notice. The company is also mandated to cooperate fully with the appointed valuer.

Analysis: Upholding Corporate Governance

SEBI's intervention in the Par Drugs case is a significant move that highlights the regulator's focus on corporate governance, especially concerning related-party transactions. By halting the deal and ordering an independent valuation, SEBI is sending a clear message that transactions must be conducted at arm's length and be demonstrably fair to all shareholders, not just the promoters. The case serves as a critical reminder of the potential for conflicts of interest in slump sales to promoter-linked entities and the crucial role of regulatory oversight in protecting minority shareholder rights. The investigation's findings could set a precedent for how similar transactions are scrutinized in the future.

The Path Forward

With the confirmatory order in place, the proposed slump sale remains suspended. The future of the transaction now hinges on the reports from the independent valuer and the merchant banker. These documents will be crucial in determining whether the proposed ₹95 crore valuation was fair. SEBI's comprehensive investigation will continue to examine potential violations of securities laws, including the Prohibition of Fraudulent and Unfair Trade Practices Regulations. Investors and the market will be closely watching for the outcome of the re-valuation and SEBI's final order, which will determine the fate of Par Drugs' core business assets.